Incinta

Based in Beijing, China and established in 2012, Incinta is a medical investment and medical institution management platform which focuses on reproduction aid technology, gene diagnose, and tumor medical treatment. In April 2025, it raised a strategic investment for USD 35 million. The company’s main business is providing precision medical services, assisted reproductive solutions, genetic diagnostics, and precision oncology, alongside medical investment and institutional operations management. The company’s self-developed technologies and platforms span assisted reproductive treatments, AI-driven embryo screening systems, and personalized cancer therapy protocols.

Its products are used in the field of fertility medicine, genetic disease screening, and tailored oncology care. Incinta generates revenue by providing assisted reproductive services, genetic testing, and precision oncology treatments, as well as through strategic investments in medical institutions and cross-border partnerships. The company will use the strategic funding for the research and development of assisted reproductive medical technology, intelligent upgrades, and expansion of the global assisted reproductive service network.